Search

Your search keyword '"Kayser, Sabine"' showing total 394 results
Start Over Author "Kayser, Sabine"
394 results on '"Kayser, Sabine"'

1. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Author

Jaramillo, Sonia, Le Cornet, Lucian, Kratzmann, Markus, Krisam, Johannes, Görner, Martin, Hänel, Mathias, Röllig, Christoph, Wass, Maxi, Scholl, Sebastian, Ringhoffer, Mark, Reichart, Alexander, Steffen, Björn, Kayser, Sabine, Mikesch, Jan-Henrik, Schaefer-Eckart, Kerstin, Schubert, Jörg, Geer, Thomas, Martin, Sonja, Kieser, Meinhard, Sauer, Tim, Kriegsmann, Katharina, Hundemer, Michael, Serve, Hubert, Bornhäuser, Martin, Müller-Tidow, Carsten, and Schlenk, Richard F.

Published
2023
Full Text
View/download PDF

2. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Author

Heitmann, Jonas S., Schlenk, Richard F., Dörfel, Daniela, Kayser, Sabine, Döhner, Konstanze, Heuser, Michael, Thol, Felicitas, Kapp-Schwoerer, Silke, Labrenz, Jannik, Edelmann, Dominic, Märklin, Melanie, Vogel, Wichard, Bethge, Wolfgang, Walz, Juliane S., Große-Hovest, Ludger, Steiner, Martin, Jung, Gundram, and Salih, Helmut R.

Published
2023
Full Text
View/download PDF

3. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Author

Smith, Catherine C, Levis, Mark J, Frankfurt, Olga, Pagel, John M, Roboz, Gail J, Stone, Richard M, Wang, Eunice S, Severson, Paul L, West, Brian L, Le, Mai H, Kayser, Sabine, Lam, Bao, Hsu, Henry H, Zhang, Chao, Bollag, Gideon, and Perl, Alexander E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Childhood Leukemia, Pediatric, Cancer, Pediatric Cancer, Hematology, Pediatric Research Initiative, Rare Diseases, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Aminopyridines, Humans, Leukemia, Myeloid, Acute, Phenylurea Compounds, Protein Kinase Inhibitors, Pyrroles, fms-Like Tyrosine Kinase 3, Cardiovascular medicine and haematology
Abstract

FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2 study evaluated the safety, tolerability, and efficacy of the oral FLT3 inhibitor PLX3397 (pexidartinib), which has activity against the FLT3 TKI-resistant F691L gatekeeper mutation in relapsed/refractory FLT3-ITD-mutant AML. Ninety patients were treated: 34 in dose escalation (part 1) and 56 in dose expansion (part 2). Doses of 800 to 5000 mg per day in divided doses were tested. No maximally tolerated dose was reached. Plasma inhibitory assay demonstrated that patients dosed with ≥3000 mg had sufficient levels of active drug in their trough plasma samples to achieve 95% inhibition of FLT3 phosphorylation in an FLT3-ITD AML cell line. Based on a plateau in drug exposure, the 3000-mg dose was chosen as the recommended phase 2 dose. The most frequently reported treatment-emergent adverse events were diarrhea (50%), fatigue (47%), and nausea (46%). Based on modified response criteria, the overall response rate to pexidartinib among all patients was 21%. Twenty-three percent of patients treated at ≥2000 mg responded. The overall composite complete response rate for the study was 11%. Six patients were successfully bridged to transplantation. Median overall survival (OS) of patients treated in dose expansion was 112 days (90% confidence interval [CI], 77-150 days), and median OS of responders with complete remission with or without recovery of blood counts was 265 days (90% CI, 170-422 days). This trial was registered at www.clinicaltrials.gov as #NCT01349049.

Published
2020

6. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

Author

Jaramillo, Sonia, Krisam, Johannes, Le Cornet, Lucian, Kratzmann, Markus, Baumann, Lukas, Sauer, Tim, Crysandt, Martina, Rank, Andreas, Behringer, Dirk, Teichmann, Lino, Görner, Martin, Trappe, Ralf-Ulrich, Röllig, Christoph, Krause, Stefan, Hanoun, Maher, Hopfer, Olaf, Held, Gerhard, Buske, Sebastian, Fransecky, Lars, Kayser, Sabine, Schliemann, Christoph, Schaefer-Eckart, Kerstin, Al-Fareh, Yousef, Schubert, Jörg, Geer, Thomas, Kaufmann, Martin, Brecht, Arne, Niemann, Dirk, Kieser, Meinhard, Bornhäuser, Martin, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Müller-Tidow, Carsten, and Schlenk, Richard F.

Published
2021
Full Text
View/download PDF

9. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease

Author

Kayser, Sabine, primary, Sartor, Chiara, additional, Giglio, Fabio, additional, Bruno, Alessandro, additional, Webster, Jonathan, additional, Chiusolo, Patrizia, additional, Saraceni, Francesco, additional, Guerzoni, Selene, additional, Pochintesta, Lara, additional, Borlenghi, Erika, additional, Marconi, Giovanni, additional, Zacheo, Irene, additional, Cerrano, Marco, additional, Salutari, Prassede, additional, Restuccia, Francesco, additional, Abbenante, Mariachiara, additional, Levis, Mark J., additional, Schlenk, Richard F., additional, and Papayannidis, Cristina, additional

Published
2023
Full Text
View/download PDF

10. International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Summary

Author

Baggio, Diva, primary, Fox, Lucy C., additional, Wood, Erica M., additional, Aditya, Robby Nur, additional, Goldman, Mindy, additional, van den Berg, Karin, additional, Kayser, Sabine, additional, Wuchter, Patrick, additional, Namba, Noriko, additional, Tsuno, Nelson H., additional, Makino, Shigeyoshi, additional, Lee, Cheuk Kwong, additional, Akhtar, Naim, additional, Shah, Farrukh, additional, Miflin, Gail, additional, Prati, Daniele, additional, La Raja, Massimo, additional, La Rocca, Ursula, additional, Richard, Pascale, additional, Tiberghien, Pierre, additional, Harley, Robert J., additional, Raouf, May Y., additional, Sharma, Ranjita, additional, Kaur, Suminder, additional, Bruijns, Sanne, additional, Prakke‐Weekamp, Henriette, additional, and Dunbar, Nancy, additional

Published
2023
Full Text
View/download PDF

11. International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Responses

Author

Baggio, Diva, primary, Fox, Lucy C., additional, Wood, Erica M., additional, Aditya, Robby Nur, additional, Goldman, Mindy, additional, van den Berg, Karin, additional, Kayser, Sabine, additional, Wuchter, Patrick, additional, Namba, Noriko, additional, Tsuno, Nelson H., additional, Makino, Shigeyoshi, additional, Lee, Cheuk Kwong, additional, Akhtar, Naim, additional, Shah, Farrukh, additional, Miflin, Gail, additional, Prati, Daniele, additional, La Raja, Massimo, additional, Rocca, Ursula La, additional, Richard, Pascale, additional, Tiberghien, Pierre, additional, Harley, Robert J., additional, Raouf, May Y., additional, Sharma, Ranjita, additional, Kaur, Suminder, additional, Bruijns, Sanne, additional, Prakke‐Weekamp, Henriette, additional, and Dunbar, Nancy, additional

Published
2023
Full Text
View/download PDF

12. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.

Author

Blüm, Philipp and Kayser, Sabine

Subjects
*THERAPEUTIC use of antineoplastic agents, *IMMUNIZATION, *SYNDROMES, *CELL transplantation, *HEMATOLOGIC malignancies, *T cells, *NEUROTOXICOLOGY, *IMMUNOTHERAPY, *CYTOKINE release syndrome, *CELLULAR therapy, *CELL receptors
Abstract

Simple Summary: This is a comprehensive overview of the approved chimeric antigen receptor T-cell products (CAR T-cells), their specific indications, treatment-related side effects, and scientific challenges. CAR T-cells have been introduced to modern hematology over the last years and have changed treatment outcomes in heavily pretreated patients with B-cell and plasma cell malignancies. To date, six commercially available CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). These advanced therapeutic medicinal products induce strong treatment effects but can also cause adverse events that can potentially be life-threatening. Therefore, a thorough understanding of CAR T-cell function and characteristics is essential for safety and efficacy. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges. Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its impact beyond hematologic malignancies. Areas of interest are, e.g., solid oncology, autoimmune diseases, infectious diseases, and others. Although much has been achieved so far, there is still a huge effort needed to overcome significant challenges and difficulties. We are witnessing a rapid expansion of knowledge, induced by new biomedical technologies and CAR designs. The era of CAR T-cell therapy has just begun, and new products will widen the therapeutic landscape in the future. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA

Author

Kayser, Sabine, primary, Sartor, Chiara, additional, Giglio, Fabio, additional, Bruno, Alessandro, additional, Webster, Jonathan, additional, Chiusolo, Patrizia, additional, Saraceni, Francesco, additional, Guerzoni, Selene, additional, Pochintesta, Lara, additional, Borlenghi, Erika, additional, Marconi, Giovanni, additional, Zacheo, Irene, additional, Cerrano, Marco, additional, Salutari, Prassede, additional, Restuccia, Francesco, additional, Abbenante, Mariachiara, additional, J Levis, Mark, additional, Schlenk, Richard, additional, and Papayannidis, Cristina, additional

Published
2023
Full Text
View/download PDF

15. PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS

Author

Kayser, Sabine, primary, Sanber, Khaled, additional, Marconi, Giovanni, additional, Mattei, Agnese, additional, Luskin, Marlise, additional, Kelkar, Amar, additional, Cerrano, Marco, additional, Sartor, Chiara, additional, Giglio, Fabio, additional, Riva, Marta, additional, Rizzo, Lorenzo, additional, Saraceni, Francesco, additional, Guerzoni, Selene, additional, Lessi, Federica, additional, Borlenghi, Erika, additional, Perl, Alexander, additional, Levis, Mark J, additional, Papayannidis, Cristina, additional, Jain, Tania, additional, and Schlenk, Richard, additional

Published
2023
Full Text
View/download PDF

17. Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study

Author

Kayser, Sabine, Rahmé, Ramy, Martínez-Cuadrón, David, Ghiaur, Gabriel, Thomas, Xavier, Sobas, Marta, Guerci-Bresler, Agnes, Garrido, Ana, Pigneux, Arnaud, Gil, Cristina, Raffoux, Emmanuel, Tormo, Mar, Vey, Norbert, de la Serna, Javier, Salamero, Olga, Lengfelder, Eva, Levis, Mark J., Fenaux, Pierre, Sanz, Miguel A., Platzbecker, Uwe, Schlenk, Richard F., Adès, Lionel, and Montesinos, Pau

Published
2021
Full Text
View/download PDF

21. Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Author

Parmar, Amanda, primary, Marz, Stefanie, primary, Rushton, Sally, primary, Holzwarth, Christina, primary, Lind, Katarina, primary, Kayser, Sabine, primary, Döhner, Konstanze, primary, Peschel, Christian, primary, Oostendorp, Robert A.J., primary, and Götze, Katharina S., primary

Published
2023
Full Text
View/download PDF

23. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Author

Kayser, Sabine, primary, Martínez-Cuadrón, David, additional, Rodriguez-Veiga, Rebeca, additional, Hänel, Mathias, additional, Tormo, Mar, additional, Schäfer-Eckart, Kerstin, additional, Botella, Carmen, additional, Stölzel, Friedrich, additional, Del Castillo, Teresa Bernal, additional, Keller, Ulrich, additional, Rodriguez-Medina, Carlos, additional, Held, Gerhard, additional, Amigo, Maria-Luz, additional, Schliemann, Christoph, additional, Colorado, Mercedes, additional, Kaufmann, Martin, additional, Garcia, Manuel Barrios, additional, Krause, Stefan W., additional, Görner, Martin, additional, Jost, Edgar, additional, Steffen, Björn, additional, Zukunft, Sven, additional, Platzbecker, Uwe, additional, Ho, Anthony D., additional, Baldus, Claudia D., additional, Serve, Hubert, additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Montesinos, Pau, additional, Röllig, Christoph, additional, and Schlenk, Richard F., additional

Published
2023
Full Text
View/download PDF

26. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

Author

Schlenk, Richard F., Kayser, Sabine, Bullinger, Lars, Kobbe, Guido, Casper, Jochen, Ringhoffer, Mark, Held, Gerhard, Brossart, Peter, Lübbert, Michael, Salih, Helmut R., Kindler, Thomas, Horst, Heinz A., Wulf, Gerald, Nachbaur, David, Götze, Katharina, Lamparter, Alexander, Paschka, Peter, Gaidzik, Verena I., Teleanu, Veronica, Späth, Daniela, Benner, Axel, Krauter, Jürgen, Ganser, Arnold, Döhner, Hartmut, and Döhner, Konstanze

Published
2014
Full Text
View/download PDF

30. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

Author

Gaidzik, Verena I., Schlenk, Richard F., Paschka, Peter, Stölzle, Anja, Späth, Daniela, Kuendgen, Andrea, von Lilienfeld-Toal, Marie, Brugger, Wolfram, Derigs, Hans Günter, Kremers, Stephan, Greil, Richard, Raghavachar, Aruna, Ringhoffer, Mark, Salih, Helmut R., Wattad, Mohammed, Kirchen, Heinz G., Runde, Volker, Heil, Gerhard, Petzer, Andreas L., Girschikofsky, Michael, Heuser, Michael, Kayser, Sabine, Goehring, Gudrun, Teleanu, Maria-Veronica, Schlegelberger, Brigitte, Ganser, Arnold, Krauter, Jürgen, Bullinger, Lars, Döhner, Hartmut, and Döhner, Konstanze

Published
2013
Full Text
View/download PDF

31. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

Author

Paschka, Peter, Du, Juan, Schlenk, Richard F., Gaidzik, Verena I., Bullinger, Lars, Corbacioglu, Andrea, Späth, Daniela, Kayser, Sabine, Schlegelberger, Brigitte, Krauter, Jürgen, Ganser, Arnold, Köhne, Claus-Henning, Held, Gerhard, von Lilienfeld-Toal, Marie, Kirchen, Heinz, Rummel, Mathias, Götze, Katharina, Horst, Heinz-August, Ringhoffer, Mark, Lübbert, Michael, Wattad, Mohammed, Salih, Helmut R., Kündgen, Andrea, Döhner, Hartmut, and Döhner, Konstanze

Published
2013
Full Text
View/download PDF

34. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

Author

Dolnik, Anna, Engelmann, Julia C., Scharfenberger-Schmeer, Maren, Mauch, Julian, Kelkenberg-Schade, Sabine, Haldemann, Berit, Fries, Tamara, Krönke, Jan, Kühn, Michael W.M., Paschka, Peter, Kayser, Sabine, Wolf, Stephan, Gaidzik, Verena I., Schlenk, Richard F., Rücker, Frank G., Döhner, Hartmut, Lottaz, Claudio, Döhner, Konstanze, and Bullinger, Lars

Published
2012
Full Text
View/download PDF

36. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

Author

Rücker, Frank G., Schlenk, Richard F., Bullinger, Lars, Kayser, Sabine, Teleanu, Veronica, Kett, Helena, Habdank, Marianne, Kugler, Carla-Maria, Holzmann, Karlheinz, Gaidzik, Verena I., Paschka, Peter, Held, Gerhard, von Lilienfeld-Toal, Marie, Lübbert, Michael, Fröhling, Stefan, Zenz, Thorsten, Krauter, Jürgen, Schlegelberger, Brigitte, Ganser, Arnold, Lichter, Peter, Döhner, Konstanze, and Döhner, Hartmut

Published
2012
Full Text
View/download PDF

37. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

Author

Kayser, Sabine, Zucknick, Manuela, Döhner, Konstanze, Krauter, Jürgen, Köhne, Claus-Henning, Horst, Heinz A., Held, Gerhard, von Lilienfeld-Toal, Marie, Wilhelm, Sibylla, Rummel, Mathias, Germing, Ulrich, Götze, Katharina, Nachbaur, David, Schlegelberger, Brigitte, Göhring, Gudrun, Späth, Daniela, Morlok, Carina, Teleanu, Veronica, Ganser, Arnold, Döhner, Hartmut, and Schlenk, Richard F.

Published
2012
Full Text
View/download PDF

40. Atypical presentation of patients with chronic myeloid leukemia in chronic phase: Case report

Author

Ramdohr, Florian, Fabarius, Alice, Maier, Bettina, Bretschneider, Daniela, Jauch, Anna, Monecke, Astrid, Metzeler, Klaus H., Janssen, Johannes W.G., Schlenk, Richard F., Kayser, Sabine, Ramdohr, Florian, Fabarius, Alice, Maier, Bettina, Bretschneider, Daniela, Jauch, Anna, Monecke, Astrid, Metzeler, Klaus H., Janssen, Johannes W.G., Schlenk, Richard F., and Kayser, Sabine

Abstract

The presence of the translocation t(9;22)(q34;q11), leading to the BCR::ABL1 fusion transcript, is the hallmark of chronic myeloid leukemia (CML). Nevertheless, atypical presentation at diagnosis can be challenging. However, although most patients with CML are diagnosed with the e13a2 or e14a2 BCR:: ABL1 fusion transcripts, about 5% of them carry rare BCR::ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3, and e6a2. In particular, the e6a2 fusion transcript has been associated with clinically aggressive disease frequently presenting in accelerated or blast crisis phases. To date, there is limited evidence on the efficacy of front-line second-generation tyrosine kinase inhibitors for this genotype. Here, we report two patients, in whom the diagnosis of CML was challenging. The use of primers recognizing more distant exons from the common BCR::ABL1 breakpoint region correctly identified the atypical BCR::ABL1 e6a2 fusion transcript. Treatment with the second-generation tyrosine kinase inhibitor nilotinib was effective in our patient expressing the atypical e6a2 BCR::ABL1 fusion transcript.

Published
2022

41. Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia

Author

Böhme, Matthias, Kayser, Sabine, Böhme, Matthias, and Kayser, Sabine

Abstract

The development and design of immune-based strategies have become an increasingly important topic during the last few years in acute myeloid leukemia (AML), based on successful immunotherapies in solid cancer. The spectrum ranges from antibody drug conjugates, immune checkpoint inhibitors blocking programmed cell death protein 1 (PD1), cytotoxic T lymphocyte antigen 4 (CTLA4) or T cell immunoglobulin and mucin domain containing-3 (TIM3), to T-cell based monoclonal and bispecific T-cell engager antibodies, chimeric antigen receptor-T-cell (CAR-T) approaches and leukemia vaccines. Currently, there are many substances in development and multiple phase I/II studies are ongoing. These trials will help us to deepen our understanding of the pathogenesis of AML and facilitate the best immunotherapeutic strategy in AML. We discuss here the mode of action of immune-based therapies and provide an overview of the available data.

Published
2022

42. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Author

Kayser, Sabine, Döhner, Konstanze, Krauter, Jürgen, Köhne, Claus-Henning, Horst, Heinz A., Held, Gerhard, von Lilienfeld-Toal, Marie, Wilhelm, Sibylla, Kündgen, Andrea, Götze, Katharina, Rummel, Mathias, Nachbaur, David, Schlegelberger, Brigitte, Göhring, Gudrun, Späth, Daniela, Morlok, Carina, Zucknick, Manuela, Ganser, Arnold, Döhner, Hartmut, and Schlenk, Richard F.

Published
2011
Full Text
View/download PDF

43. Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD

Author

Jaramillo, Sonia, primary, Cornet, Lucian Le, additional, Kratzmann, Markus, additional, Krisam, Johannes, additional, Görner, Martin, additional, Hänel, Mathias, additional, Röllig, Christoph, additional, Wass, Maxi, additional, Scholl, Sebastian, additional, Ringhoffer, Mark, additional, Reichart, Alexander, additional, Steffen, Björn, additional, Kayser, Sabine, additional, Mikesch, Jan-Henrik, additional, Schaefer-Eckart, Kerstin, additional, Schubert, Jörg, additional, Geer, Thomas, additional, Martin, Sonja, additional, Kieser, Meinhard, additional, Sauer, Tim, additional, Kriegsmann, Katharina, additional, Hundemer, Michael, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Müller-Tidow, Carsten, additional, and Schlenk, Richard F., additional

Published
2022
Full Text
View/download PDF

44. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Author

Kayser, Sabine, primary, Martínez-Cuadrón, David, additional, Hanoun, Maher, additional, Stölzel, Friedrich, additional, Gil, Cristina, additional, Reinhardt, H. Christian, additional, Aguiar, Eliana, additional, Schäfer-Eckart, Kerstin, additional, Burgues, Juan Miguel Bergua, additional, Steffen, Björn, additional, Bernal, Teresa, additional, Krause, Stefan W., additional, Riaza, Rosalía, additional, Schliemann, Christoph, additional, Cervera, Jose, additional, Kaufmann, Martin, additional, Torres-Miñana, Laura, additional, Hänel, Mathias, additional, Acuña-Cruz, Evelyn, additional, Jost, Edgar, additional, Algarra, Jesus Lorenzo, additional, Crysandt, Martina, additional, Fransecky, Lars, additional, Cornago-Navascues, Javier, additional, Kraus, Sabrina, additional, Martinez-Lopez, Joaquin, additional, Einsele, Hermann, additional, Niemann, Dirk, additional, Neubauer, Andreas, additional, Seggewiß-Bernhardt, Ruth, additional, Scholl, Sebastian, additional, Klein, Stefan A., additional, Schmid, Christoph, additional, Schaich, Markus, additional, Schmidt-Hieber, Martin, additional, Zukunft, Sven, additional, Ho, Anthony D., additional, Platzbecker, Uwe, additional, Baldus, Claudia D., additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, Levis, Mark, additional, Montesinos, Pau, additional, Röllig, Christoph, additional, and Schlenk, Richard F., additional

Published
2022
Full Text
View/download PDF

45. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin

Author

Kayser, Sabine, primary, Sartor, Chiara, additional, Luskin, Marlise R., additional, Webster, Jonathan, additional, Giglio, Fabio, additional, Panitz, Nydia, additional, Brunner, Andrew M., additional, Fante, Matthias, additional, Lutz, Christoph, additional, Wolff, Daniel, additional, Ho, Anthony D., additional, Levis, Mark J., additional, Schlenk, Richard F., additional, and Papayannidis, Cristina, additional

Published
2022
Full Text
View/download PDF

46. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report

Author

Kurch, Lars, primary, Georgi, Thomas W., additional, Monecke, Astrid, additional, Seehofer, Daniel, additional, Borte, Gudrun, additional, Sabri, Osama, additional, Kluge, Regine, additional, Heyn, Simone, additional, Pierer, Matthias, additional, Platzbecker, Uwe, additional, and Kayser, Sabine, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results